BirthME, Doulas

HQ Phone (475) 230-2596. View Betel Girmay's business profile as Global Director, Clinical Operations at Alexion Pharmaceuticals Inc. Find contact's direct phone number, email address, work history, and more. Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. Credit Suisse Group upped their target price on Alexion Pharmaceuticals from $142.00 to $147.00 and gave the stock an “outperform” rating in a research report on Monday, June 1st. The firm has a market cap of $22.33 billion, a PE ratio of … Head of Learning Alexion Pharmaceuticals, Inc. Several equities research analysts have recently weighed in on the company. Health Coach Manager- Fitbit Health Solutions. ) as a momo momentum candidate. Alexion is a global biopharmaceutical company focused on the discovery, development, and commercialization of medicines for severe and life-threatening rare dis... Alexion’s headquarters are in 121 Seaport Blvd, Boston, Massachusetts, 02210, United StatesAlexion is in the industry of: Drug Manufacturing & Research, Pharmaceuticals, HealthcareAlexion's main competitors are: Jazz Pharmaceuticals plc, Seattle Genetics , Inc., Ultragenyx Pharmaceutical Inc, United Therapeutics CorporationAlexion has acquired the companies: Portola Pharmaceuticals, Strensiq, Syntimmune Inc, Wilson Therapeutics ABThis content is available only for ZoomInfo customers121 Seaport Blvd, Boston, Massachusetts, 02210, United StatesBOSTON--(BUSINESS WIRE)--Alexion Announces Appointment of First Chief Diversity OfficerIn October 2019, Alexion Pharmaceuticals snapped up Achillon Pharmaceuticals and its oral small molecule Factor D inhibitor program for a rare kidney disease for $930 million in cash. 5/18/2020 6:34 AM.

Market technicians refer to such stocks as being in a mark-up phase before a possible distribution period and price decline. Hillsdale Investment Management Inc. now owns 4,470 shares of the biopharmaceutical company’s stock valued at $401,000 after acquiring an additional 100 shares during the period. Our Medicines Our Company Everything was fine for about two weeks.”As a father of two young children, Donnan recalls being afraid of what the future would hold prior to his diagnosis.Married with a newborn son, Ruthie was scared to learn that PNH was a life-threatening illness that at the time had no approved treatment.At only three months old, Evie's parents were told that her case was severe and that there were no approved or effective treatment options.Despite having a constant struggle with symptoms, Roberta revisited her dreams and put herself through nursing school.Tristan's parents experienced a whirlwind of emotions and fear after learning their 5-year-old son had such a rare and serious disease.The work we do is guided by people living with rare and devastating diseases. Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, July 30th. Head of Learning. Louisiana State Employees Retirement System now owns 9,500 shares of the biopharmaceutical company’s stock worth $1,066,000 after buying an additional 100 shares during the period. Now we knew what we were up against, we knew we could fight.”This website is intended only for residents of the United States. 89.07% of the stock is owned by hedge funds and other institutional investors. We use cookies to give you the best online experience. 3 hours ago. Alexion Pharmaceuticals, Inc. has a 52 week low of $72.67 and a 52 week high of $125.52.

Equities analysts forecast that Alexion Pharmaceuticals, Inc. will post 9.99 earnings per share for the current year. REGN | Complete Regeneron Pharmaceuticals Inc. stock news by MarketWatch.

The Alexion Charitable Foundation awarded a total of $1.1 million in initial grants that align with its Rare Belonging® focus. Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.Trade-Ideas LLC identified Alexion Pharmaceuticals (ALXN) as a momo momentum candidate© 2020 TheStreet, Inc. All rights reserved. While at XOMA, Al led several successful CMC collaborations with companies like Chiron, Novartis, Pfizer, Aveo Pharmaceuticals, Alexion, Department of Defense and Servier to name a few for antibody process development and manufacturing by XOMA. In addition to specific proprietary factors, Trade-Ideas identified Alexion Pharmaceuticals as such a stock due to the following factors: We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. To report an adverse event experience for any Alexion product please contact us at AdverseEventReporting@alexion.com or 1-844-259-6783. Technical analysts and traders frequently find that the factors referenced above tend to create a temporary burst of strong wind in a stock's sail. M&T Bank Corp purchased a new stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). Credit Agricole S A boosted its position in shares of Alexion Pharmaceuticals by 25.0% in the first quarter. Alexion Pharmaceuticals had a net margin of 15.28% and a return on equity of 22.57%.

We are driven to continuously innovate and create meaningful value in all we do to help patients and families fully live their best lives. Get Email Address. The biopharmaceutical company reported $3.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.32 by $0.79. View Dan Carlin's business profile as Scientist II, Biomarkers at Alexion Pharmaceuticals Inc. Find contact's direct phone number, email address, work history, and more.